麻豆传媒

Dr. Parker is a senior fellow for the Pandemic and Biosecurity Policy Programs at the Scowcroft Institute of International Affairs, Bush School of Government and Public Service; associate dean for Global One Health, Texas A&M College of Veterinary Medicine

Dr. Patterson’s laboratory works on the development of countermeasures against potential biological weapons. Her group focuses on the development of therapies and vaccines against naturally occurring pathogens that can cause sporadic but lethal outbreaks, and her most recent studies concentrate on hemorrhagic fever viruses. Dr. Patterson has been involved in the development of three vaccines against Ebola and two vaccines against Lassa fever that are undergoing further studies. Her lab utilizes the maximum containment laboratory (BSL-4) at Texas Biomed. Dr. Patterson helped develop a marmoset model used for multiple infectious agents: Ebola virus Marburg virus Lassa fever Eastern Equine Encephalitis virus

Dr. Garc铆a-Sastre is a Professor in the Department of Microbiology and Director of the Global Health and Emerging Pathogens Institute of Icahn School of Medicine at Mount Sinai in New York. For the past 25 years, his research interest has been focused on the molecular biology of influenza viruses and several other negative-strand RNA viruses. During his post-doctoral training in the early 1990s, he developed, for the first time, novel strategies for expression of foreign antigens by a negative-strand RNA virus, influenza virus. He has made major contributions to the influenza virus field, including 1) the development of reverse genetics techniques allowing the generation of recombinant influenza viruses from plasmid DNA, (studies in collaboration with Dr. Palese); 2) the generation and evaluation of negative-strand RNA virus vectors as potential vaccine candidates against different infectious diseases, including malaria and AIDS, and 3) the identification of the biological role of the non-structural protein NS1 of influenza virus during infection: the inhibition of the type I interferon (IFN) system. His studies provided the first description and molecular analysis of a viral-encoded IFN antagonist among negative-strand RNA viruses.  These studies led to the generation of attenuated influenza viruses containing defined mutations in their IFN antagonist protein that might prove to be optimal live vaccines against influenza. His research has resulted in more than 480 scientific publications and reviews. Dr. Garc铆a-Sastre is the director of the Center for Research on Influenza Pathogenesis (CRIP), one of the five NIAID funded Centers of Excellence for Influenza Research and Surveillance. He was among the first members of the Vaccine Study Section and member of the Virology B Study Section of NIH. In addition, he has served for 5 years as Editor of Journal of Experimental Medicine, is Editor of PLoS Pathogens, Journal of Virology and Virus Research, and member of the Editorial Board of Virology, Vaccine, NPJ Vaccines and Influenza and Other Respiratory Diseases.  He is a member of the scientific advisory board of Keystone Symposia. He has been a co-organizer of the international course on Viral Vectors (2001), held in Heidelberg, Germany, sponsored by Federation of European Biochemical Societies (FEBS), and of the first Research Conference on Orthomyxoviruses in 2001, held in Texel, The Netherlands, sponsored by the European Scientific Working Group on Influenza (ESWI). He has also been a co-organizing of the 7th International Society for Vaccines meeting in 2013, and of Keystone Meetings in 2014 on Respiratory Virus Pathogenesis and in 2017 on Interferons. His publication in Science on the reconstruction and characterization of the pandemic influenza virus of 1918 has been awarded the distinction of the paper of the year 2005 by Lancet. In 2005, he became a Fellow of the American Academy of Microbiology, and in 2009, he received the Beijerink Professorship from the National Academy of Sciences of the Netherlands. In 2011, he has been elected President of the International Society for Vaccines, for 2014 and 2015. In 2017, he has been elected a fellow of the Royal Academy of Pharmacy in Spain.

Dr. Monique K. Mansoura joined The MITRE Corporation as the Executive Director for Global Health Security and Biotechnology in September 2017. She brings technical, policy and business expertise from both the public and private sectors. Her current efforts focus on the sustainability of the biodefense industrial base and the public-private partnerships that are vital to national and global health security as well as the bioeconomy. These issues are especially relevant to the challenges our nation and the world faces in addressing threats such as the 2019 Novel Coronavirus (2019-nCoV) and the surety and security of medical supply chains.

She is an internationally recognized executive in the biopharma industry and biomedical research and development ecosystem (industry, government, and academia) with proven success designing and driving missions of international importance through innovative public-private partnerships, particularly in market-challenged environments. She brings unique skills and perspectives given training and expertise in business, science, and policy. She has been deeply engaged with two of the most vital issues of our times 鈥� the Human Genome Project (1996-2001) and Biodefense/Global Health Security (2002-present) for threats including chemical, biological, radiological and nuclear (CBRN) agents, pandemic influenza and other emerging infectious diseases. Her pivotal career transition was driven by a call to service following 9/11 and the 2001 anthrax attacks. She led strategic policy, planning and budgeting for a pioneering multibillion-dollar medical countermeasure development and acquisition program in the U.S. that still stands a model for the world under the authorities of the Project BioShield Act of 2004 and the Pandemic and All-Hazards Preparedness Act of 2006. She has been a successful senior leader in Government and industry by building effective teams across diverse organizations and functions, developing talent, leveraging multi-stakeholder networks through effective engagement with partners in biotech and multinational companies, academia, professional and patient advocacy organizations and international governments through the Global Health Security Initiative. She served on the Board of the Alliance for Biosecurity from 2012-2016 and is currently on the Board of the International Cancer Expert Corps (ICEC).

During a recent sabbatical, Monique examined innovative financing approaches in healthcare as a Research Affiliate of the MIT Laboratory for Financial Engineering (LFE), Sloan School of Management. She led an LFE healthcare finance initiative in global health security with Professor Andrew Lo and his colleagues. This initiative explored new business models and financial vehicles for raising and deploying funds to enhance global health security.

In 2018, Dr. Mansoura participated in the Public-Private Analytic Exchange Program sponsored by the Office of the Director of National Intelligence. Her team developed a report in July 2018 on 鈥淭hreats to Pharmaceutical Supply Chains鈥� focusing on Hurricane Maria and the 2017-2018 seasonal influenza epidemic as a case study for the risks and implications of pharmaceutical supply chain disruptions.

Monique earned a PhD in Bioengineering and a M.S. in Human Genetics from the University of Michigan, a B.S. in Chemical Engineering from Wayne State University, and an MBA in the Sloan Fellows Program in Innovation and Global Leadership at MIT.

Jay Schnitzer is senior vice president, chief technology officer, and chief medical officer at The MITRE Corporation. In this role, he directs the organization鈥檚 independent research and development (R&D) program and manages development of corporate technology strategy, which spans MITRE鈥檚 operating centers and sponsor community. He also leads corporate and national initiatives in health and life sciences, building coalitions leveraging the best talent across the nation in these communities.

Previously, as the director of biomedical sciences at MITRE, Schnitzer oversaw the organization鈥檚 health transformation R&D program. In that capacity, he identified opportunities for MITRE to make important, transformative, and impactful differences in healthcare for our sponsors and the nation. As part of this work, he led the writing and editing of the Integrated Report for the Independent Assessment performed in response to Section 201 of the Veterans Choice Act and organized and facilitated the Blue-Ribbon Panel. To support the Department of Veterans Affairs鈥� (VA) decision on its electronic health record (EHR) system, he facilitated a special Listening Forum for the VA Secretary in August 2017, at which industry experts on EHR implementation discussed leading practices. In January 2018, he organized a panel of EHR interoperability experts, which produced a report containing recommendations as input for the VA鈥檚 contract with a commercial EHR vendor.

Before joining MITRE, Schnitzer was the director of the Defense Sciences Office at DARPA, where he led a team of 20 program managers and 70 support staff overseeing R&D across multiple domains. In addition to life sciences, biomedical research, and quantum physics, these R&D areas included materials science, advanced mathematics, and engineering. 

Formerly, Schnitzer was chief medical officer and senior vice president at Boston Scientific Corporation (BSC). His responsibilities at BSC included medical and clinical oversight of the entire product lifecycle for all medical devices manufactured by four business divisions of the company: endoscopy, urology/women鈥檚 health, neurovascular, and neuromodulation.

Prior to BSC, Schnitzer was on staff at Massachusetts General Hospital as an attending pediatric surgeon, with a joint appointment at the Shriners Hospital for Children burn center and a faculty position at Harvard Medical School.

In recognition of his work on the COVID-19 Healthcare Coalition and his leadership of the MITRE independent R&D program, WashingtonExec named Schnitzer its 2020 Healthcare Industry Executive of the Year. The award recognizes executives fostering innovation for the federal government.

Schnitzer received a B.S. degree in chemical engineering from Worcester Polytechnic Institute, a Ph.D. in chemical engineering from MIT, and an M.D. from Harvard Medical School. He is board certified and re-certified in surgery and pediatric surgery.